Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

ODYSSEY data mining

ACS EuroPath Survey

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers1,2

Managing dyslipidemia in your ASCVD patients according to the new guidelines

The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation

Rilzabrutinib a BTK inhibitor

Complex immune dysregulation impact on QoL

Interplay between the innate and adaptive immunity

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

Prevalence of Type 1 Diabetes and Daily Life Impact

Expert thoughts on the rising prevalence of Type 1 Diabetes and its implications for public health. Type 1 diabetes represents few diabetes cases globally, creating both physical and psychological challenges.

Stages of Type 1 Diabetes and DKA Impact

Type 1 diabetes progresses from presymptomatic autoimmunity to symptomatic hyperglycemia, ultimately requiring lifelong insulin therapy. DKA can cause severe metabolic imbalances requiring hospitalization, significantly disrupting daily life and posing serious health risks.